Journal

Expert consensus on palivizumab use for respiratory syncytial virus in developed countries

Read time: 1 mins

Published:31st Jan 2020

Author: Luna MS, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A et al.

Source: Paediatric Respiratory Reviews

Availability: Pay for access, or by subscription

Ref.:Paediatr Respir Rev. 2020 Feb;33:35-44.

DOI:10.1016/j.prrv.2018.12.001

Expert consensus on palivizumab use for respiratory syncytial virus in developed countries

Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to cost-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. Almost 400 publications were reviewed. This group recommended palivizumab for: preterm infants (<29 and ≤31 weeks gestational age [wGA] and ≤9 and ≤6 months of age, respectively; high-risk 32-35wGA), former preterm children ≤24 months with chronic lung disease/bronchopulmonary dysplasia, children ≤24 months with significant congenital heart disease; and other high-risk populations, such as children ≤24 months with Down syndrome, pulmonary/neuromuscular disorders, immunocompromised, and cystic fibrosis. Up to 5 monthly doses should be administered over the RSV season. It is our impression that the adoption of these guidelines would help reduce the burden of RSV.

Read abstract on library site Access full article